Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 63,127
- 主要终点
- Change from baseline in breathlessness when walking/climbing stairs
研究概览
简要总结
As part of the post-marketing surveillance, information is to be gathered regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women aged at least 40 years presenting with the symptoms of COPD
排除标准
- •Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information
研究组 & 干预措施
Symptoms of COPD
Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
干预措施: Tiotropium bromide (Drug)
结局指标
主要结局
Change from baseline in breathlessness when walking/climbing stairs
时间窗: Baseline, after 4 weeks
Change from baseline in overall severity of the clinical picture
时间窗: Baseline, after 4 weeks of treatment
Occurrence of Adverse Events
时间窗: up to 4 weeks
Change from baseline in breathlessness on Physical exercise
时间窗: Baseline, after 4 weeks
Change from baseline in breathlessness during housework
时间窗: Baseline, after 4 weeks
Change from baseline in breathlessness during everyday activities
时间窗: Baseline, after 4 weeks
次要结局
未报告次要终点